
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Scholar Rock Holding Corp (SRRK)




- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: SRRK (5-star) is a STRONG-BUY. BUY since 21 days. Profits (13.42%). Updated daily EoD!
1 Year Target Price $49.67
1 Year Target Price $49.67
6 | Strong Buy |
4 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 180.2% | Avg. Invested days 36 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.55B USD | Price to earnings Ratio - | 1Y Target Price 49.67 |
Price to earnings Ratio - | 1Y Target Price 49.67 | ||
Volume (30-day avg) 10 | Beta 0.3 | 52 Weeks Range 6.76 - 46.98 | Updated Date 07/12/2025 |
52 Weeks Range 6.76 - 46.98 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.15% | Return on Equity (TTM) -106.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3253529841 | Price to Sales(TTM) 13.14 |
Enterprise Value 3253529841 | Price to Sales(TTM) 13.14 | ||
Enterprise Value to Revenue 8.22 | Enterprise Value to EBITDA -2.08 | Shares Outstanding 94945600 | Shares Floating 79233021 |
Shares Outstanding 94945600 | Shares Floating 79233021 | ||
Percent Insiders 4.35 | Percent Institutions 118.63 |
Upturn AI SWOT
Scholar Rock Holding Corp

Company Overview
History and Background
Scholar Rock Holding Corp. is a biopharmaceutical company focused on discovering and developing medicines for the treatment of serious diseases in which protein growth factors play a fundamental role. Founded in 2012, the company is headquartered in Cambridge, Massachusetts. Scholar Rock's approach targets the molecular mechanisms of growth factor activation for greater therapeutic selectivity and efficacy.
Core Business Areas
- TGFu03b2 Inhibitors: Focuses on developing inhibitors of Transforming Growth Factor beta (TGFu03b2) superfamily proteins to treat diseases characterized by fibrosis, muscle atrophy, and anemia.
- SRK-181: SRK-181 is a selective inhibitor of latent myostatin activation designed to treat spinal muscular atrophy (SMA).
Leadership and Structure
Nagesh Mahanthappa is the President and CEO. The company has a board of directors that provides strategic oversight. The organizational structure includes research and development, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- Apitegromab: A selective inhibitor of myostatin activation. Focuses on treatment of Spinal Muscular Atrophy (SMA). The drug is currently in clinical development. There is no current market share data available, it is in Phase 3 clinical trial. Competitors include Biogen, Roche, and Novartis who already have approved SMA treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by lengthy and expensive development processes, stringent regulatory requirements, and significant patent protection.
Positioning
Scholar Rock is positioned as a company focused on growth factor biology with a pipeline of targeted therapies. Its competitive advantage lies in its proprietary platform for selective inhibition of growth factor activation.
Total Addressable Market (TAM)
The total addressable market is variable, but for Spinal Muscular Atrophy (SMA) treatments, it is projected to be in the billions of dollars. Scholar Rock is positioning itself within this TAM by developing a novel myostatin inhibitor to address unmet needs in SMA treatment.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform targeting growth factor activation
- Strong scientific team with expertise in growth factor biology
- Focused pipeline addressing unmet medical needs
- Partnerships with leading research institutions
Weaknesses
- Limited commercial infrastructure as a development-stage company
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Reliance on external funding
Opportunities
- Potential to expand pipeline through internal research and development
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion into new therapeutic areas
- Positive clinical trial results driving stock value
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Roche (RHHBY)
- Novartis (NVS)
Competitive Landscape
Scholar Rock's advantages lie in its targeted approach to growth factor inhibition. Disadvantages include its limited commercial resources compared to larger pharmaceutical companies. Current market share for SRRK is effectively zero as they do not yet have an approved product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D expenses and clinical trial advancements.
Future Projections: Future growth is contingent on successful clinical trial outcomes and partnerships.
Recent Initiatives: Recent initiatives include advancing apitegromab into Phase 3 clinical trials and seeking partnerships.
Summary
Scholar Rock is a development-stage biopharmaceutical company focusing on growth factor inhibition. Its strength lies in its novel technology and pipeline, but weaknesses include limited commercial infrastructure and dependence on clinical trial outcomes. Positive clinical trial results and partnerships are crucial for its success, while regulatory hurdles and competition pose significant risks. The company's future is uncertain given its R&D nature.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scholar Rock Holding Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. David L. Hallal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.scholarrock.com |
Full time employees 128 | Website https://www.scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.